|
Objective: To detect obstructive sleep apnea hypopnea syndrome (OSAHS) patients with fasting serum visfatin levels, analyze it and lipids, insulin resistance level, body mass index, waist-hip ratio, AHI index, explore OSAHS patients The reason for the change in the level of serum visfatin its role in the the OSAHS progression in. METHODS: We randomly select the OSAHS group of 50 cases and normal control group 35 patients with OSAHS groups based on body mass index is divided into OSAHS obese group (BMI ≥ 28kg/m2) 26 Li with OSAHS non-obese group (BMI lt; 28 kg/m2) 24 Li . All subjects underwent all night 7h polysomnography respiratory monitoring, record apnea hypopnea index (AHI) and lowest SaO2 average SaO2, SaO2 lt; 90% of the time. Object of measurement of height, weight, neck circumference, waist circumference, abdominal circumference, hip circumference, calculation of body mass index (BMI) and waist-to-hip ratio (WHR). Enzyme-linked immunosorbent assay measurement of serum visfatin, insulin levels, and homeostasis model assessment (HOMA) insulin resistance index (HOMA-IR), the biochemical analyzer blood sugar, TC, TG, HDL-C, of ??LDL-C level. Serum visfatin levels comparison OSAHS group and the control group, the difference between the HOMA-IR in serum lipids and analysis of serum visfatin levels and BMI, WHR, neck circumference, waist circumference, abdominal circumference, hip circumference, apnea-hypopnea index (AHI), lowest oxygen saturation TC The correlation between TG, HDL-C, LDL-C, glucose, insulin, HOMA-IR. Results: (1) in OSAHS group, fasting serum visfatin levels significantly higher than the normal control group, a significant difference (p lt; 0.01); visfatin with OSAHS obese group serum levels higher than the the OSAHS non-obese group, but there was no significant difference (p gt; 0.05); OSAHS non-obese group serum visfatin levels higher than the normal control group, but the two there was no significant difference (p gt; 0.05); visfatin with OSAHS obesity serum was significantly higher than that of the control group, there is a significant difference (P lt; 0.01). 2. In OSAHS group glucose, TC of HDL-C, LDL-C and the control group compared to the differences in sex (P lt; 0.05), AHI and LDL-C, blood glucose, TG was significantly positive related (p-lt; 0.05) , AHI and HDL-C was significantly negatively correlated (p lt; 0.05). AHI stepwise multiple linear regression analysis showed that 90% of the time and the lowest SaO2 neck circumference increases the AHI the risk factors (p lt; 0.05) the AHI SaO2 lt; impact factors (p lt; 0.05) . Serum visfatin levels and BMI, WHR, neck circumference, waist circumference, abdominal circumference, Hip, AHI, blood glucose, insulin, HOMA-IR, TC, TG showed a significant positive correlation (p lt; 0.05) and the lowest SaO2 The average SaO2 showed a significant negative correlation (p lt; 0.05). 5. Internal visfatin stepwise multiple linear regression analysis showed that the insulin resistance, and neck circumference increased serum visfatin levels of risk factors (p lt; 0.01). Conclusion: patients with OSAHS presence of glucose, dyslipidemia and lipid disorders with OSAHS severity of the disease. 2 increased neck circumference is a risk factor for OSAHS. 3. Insulin resistance and increased neck circumference are risk factors that lead to elevated levels of serum visfatin. 4. OSAHS and obesity have elevated level of serum visfatin trends, the level of serum visfatin with OSAHS severity of the disease, lipid disorders related. Serum visfatin levels change as one of the OSAHS predictors of concurrent lipid disorders.
|